Literature DB >> 11189012

Leukocytes in the early events of corneal neovascularization.

L Gan1, P Fagerholm.   

Abstract

PURPOSE: To study the early events in corneal neovascularization after alkali injury and their relationship to the presence and absence of leukocytes.
METHODS: A standardized 5.5-mm diameter penetrating central corneal alkali wound was induced in one eye in each of ten New Zealand white rabbits (2.5 kg). In five of the ten rabbits, 1.5 mL 5% fucoidin was given intravenously every 2 hours to prevent leukocytes from leaving the blood stream. Presence of hyaluronan (HA) and proliferating cell nuclear antigen (PCNA) in the corneas were analyzed using immunohistochemical staining 36 hours after injury.
RESULTS: In the alkali wounded corneas, HA was expressed intensively in the limbal area where a massive infiltration of leukocytes was seen. PCNA was expressed in the vascular endothelium as well as in the corneal cells. In the leukocyte-free corneas, HA staining intensity and distribution were the same as in uninjured corneas. No positive PCNA staining was seen in the vascular endothelial cells in these corneas.
CONCLUSIONS: Extravasated leukocytes in the alkali-burned corneas caused enhanced production of HA and proliferation of vascular endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11189012     DOI: 10.1097/00003226-200101000-00018

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  3 in total

1.  Multi-gene targeted antiangiogenic therapies for experimental corneal neovascularization.

Authors:  Peng Chen; Hongmei Yin; Yao Wang; Jing Mi; Wenxiao He; Lixin Xie; Yiqiang Wang
Journal:  Mol Vis       Date:  2010-02-27       Impact factor: 2.367

2.  S100A proteins in the pathogenesis of experimental corneal neovascularization.

Authors:  Changyou Li; Feng Zhang; Yiqiang Wang
Journal:  Mol Vis       Date:  2010-10-31       Impact factor: 2.367

3.  Comparison of different doses of subconjunctival sunitinib with bevacizumab in the treatment of corneal neovascularization in experimental rats.

Authors:  Mohammad Nasser Hashemian; Hadi Z Mahrjerdi; Mehdi Mazloumi; Mona S Safizadeh; Yadollah Shakiba; Firouzeh Rahimi; Mohsen Afarideh; Mohamad Ali Zare; Mohammadreza Fallah Tafti; Bahram Bohrani Sepidan; Mohammad Ali Abtahi; Seyed-Hossein Abtahi
Journal:  J Res Med Sci       Date:  2017-02-16       Impact factor: 1.852

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.